Elsevier,

Manson's Tropical Diseases (Twentyfourth Edition)
2024, Pages 101-109

This content aligns with Goal 3: Good Health and Wellbeing as well as Goal 10: Reduced Inequalities by providing information about access to evidence-based treatment and prevention interventions as well as addressing the underlying social, political and economic issues, such as poverty, lack of access to healthcare, and stigma and discrimination that contribute to the high burden of HIV in the region
Elsevier,

Reproductive BioMedicine Online, Available online 12 October 2023, 103600

This article ties with climate action and reproductive medicine, as it is a reflexion on healthcare carbon footprint especially the IVF laboratories.
WHO recommends dolutegravir as the preferred anchor drug for first-line and second-line HIV treatment, and is being rolled out globally. This study shows that dolutegravir is safe but clinicians should nonetheless be aware of the risk of psychiatric manifestations in children and adolescents taking the drug.
This Article supports SDG 3 by showing, through a modelling analysis, that community tenofovir, lamivudine, and dolutegravir (TLD) is likely to reduce HIV incidence and be cost-effective, thus leading to population health benefits.
This Article supports SDG 3 by showing that interventions and strategies to reduce mortality from HIV-related CNS infection in public hospitals within routine care services can substantially reduce all-cause 2-week mortality among people living with HIV presenting to public hospitals with suspected HIV-related CNS infection.

World Patient Safety Day 2024

World Animal Day exists to raise the status of animals and improve welfare standards around the globe.
It’s a day of celebration for animal lovers everywhere.

In The World We Want we explore key themes related to the SDGs: leadership, innovation and youth. Dr. Márcia Balisciano, Global Head of Corporate Responsibility, interviews influencers and thought leaders across disciplines on key topics to achieve the global goals.
Elsevier,

The Lancet Psychiatry, Volume 10, October 2023

This commentary describes the contributions people from minority groups with mental illness can make to mental health research.
This Article supports SDG 3 by analysing 40 studies from Latin America to find a lifetime prevalence of depressive disorder in this region of 12.6%, and a current prevalence of 3.1%. The authors note that after adjusting for income and using the same inclusion criteria and assessment methods, these estimates may be higher than global estimates provided by previous systematic reviews; however, more mental health research is needed in the region to generate more definitive conclusions.

Pages